Denmark’s Vaccination Research has been approved by the EU

The European Commission has authorized a €108 million Danish aid package to support Bavarian Nordic, a vaccine development and production company, with coronavirus-related research and development (R&D). The project was approved under the Temporary Framework for State Aid.

The €108 million Danish aid package, according to Executive Vice-President Margrethe Vestager, who is in charge of competition policy, will help fund much-needed research and development operations in response to the coronavirus pandemic.

Under the Temporary Framework, Denmark notified the Commission of a €108 million aid package to support coronavirus-related R&D operations of Bavarian Nordic, a big company active in vaccine development and manufacture in Denmark and Germany. The public assistance will be in the form of a repaid loan.

The measure’s goal is to help fund the development of a new coronavirus vaccine produced by AdaptVac and licensed to Bavarian Nordic. Phase II clinical studies for the proposed vaccine are now underway.

The funds will go toward the next stages of research, such as the phase III study to validate safety and efficacy, the experimental development of the essential manufacturing methods, and the work required to obtain regulatory approvals.

Photo Credit: